| 國立成功大學 |
2022 |
Robust Lane Detection via Filter Estimator and Data Augmentation
|
Zhang, Y.-M.;Lin, S.-W.;Chou, T.-H.;Jhong, S.-Y.;Chen, Y.-Y. |
| 國立成功大學 |
2022 |
Dynamic Assertions for Quantum Circuits Based on Stabilizers
|
Lin, C.-Y.;Lin, S.-W.;Chen, Y.-R. |
| 臺大學術典藏 |
2021-12-02T05:41:27Z |
False-positive Aspergillus galactomannan immunoassays associated with intravenous human immunoglobulin administration
|
WANG-DA LIU; Lin S.-W.; Shih M.-C.; Su C.-L.; Wang Y.-W.; Lin S.-C.; Lee Y.-F.; Huang H.-H.; Chou W.-C.; Wu U.-I.; Chen Y.-C.; Chang S.-C. |
| 臺大學術典藏 |
2021-12-01T06:02:06Z |
Implementation and outcomes of a therapeutic drug monitoring program for antifungal and antiretroviral agents in a tertiary medical center in Taiwan
|
Lin S.-W.; Kuo C.-H.; Shen L.-J.; YEE-CHUN CHEN; Hung C.-C.; Wu F.-L.L. |
| 臺大學術典藏 |
2021-12-01T02:29:07Z |
Effectiveness of half-a-tablet efavirenz plus 2 nucleos(t)ide reverse-transcriptase inhibitors as maintenance therapy with the guidance of therapeutic drug monitoring among virologically suppressed HIV-positive patients: A prospective study
|
Huang S.-H.; Lin S.-W.; Chang S.-Y.; Lin Y.-T.; Sun H.-Y.; Liu W.-C.; Su Y.-C.; CHIEN-CHING HUNG; Chang S.-C. |
| 臺大學術典藏 |
2021-12-01T02:29:03Z |
Implementation and outcomes of a therapeutic drug monitoring program for antifungal and antiretroviral agents in a tertiary medical center in Taiwan
|
Lin S.-W.; Kuo C.-H.; Shen L.-J.; Chen Y.-C.; CHIEN-CHING HUNG; Wu F.-L.L. |
| 臺大學術典藏 |
2021-09-27T05:32:36Z |
Influenza vaccination and the risk of COVID-19 infection and severe illness in older adults in the United States
|
Huang K.; Lin S.-W.; WANG-HUEI SHENG; Wang C.-C. |
| 臺大學術典藏 |
2021-09-17T05:58:15Z |
Augmented renal clearance is associated with inadequate antibiotic pharmacokinetic/ pharmacodynamic target in Asian ICU population: a prospective observational study
|
Wu C.-C.; CHIH-HSUN TAI; Liao W.-Y.; Wang C.-C.; Kuo C.-H.; Lin S.-W.; Ku S.-C. |
| 臺大學術典藏 |
2021-09-17T05:58:15Z |
Safety of high-dose daptomycin in patients with severe renal impairment
|
CHIH-HSUN TAI; Shao C.-H.; Chen C.-Y.; Lin S.-W.; Wu C.-C. |
| 臺大學術典藏 |
2021-09-17T02:50:56Z |
Isoniazid concentration and NAT2 genotype predict risk of systemic drug reactions during 3HP for LTBI
|
MENG-RUI LEE; Huang H.-L.; Lin S.-W.; Cheng M.-H.; Lin Y.-T.; Chang S.-Y.; Yan B.-S.; Kuo C.-H.; Lu P.-L.; Wang J.-Y.; Chong I.-W. |
| 臺大學術典藏 |
2021-08-31T03:33:43Z |
Completion and adverse drug events of latent tuberculosis infection treatment in patients receiving dialysis: Predictors and impacts of different regimens in a prospective cohort study
|
SHU-YUNG LIN; Feng J.-Y.; Lee C.-Y.; Lin Y.-C.; Chou Y.-H.; Lin K.-Y.; Wei Y.-F.; Lin S.-W.; Chang C.-H.; Wang P.-H.; Shu C.-C.; Wang J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-31T03:33:43Z |
CD4 response of QuantiFERON-TB Gold Plus for positive consistency of latent tuberculosis infection in patients on dialysis
|
Wang P.-H.; SHU-YUNG LIN; Lee S.S.-J.; Lin S.-W.; Lee C.-Y.; Wei Y.-F.; Shu C.-C.; Wang J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-27T06:48:56Z |
Cholelithiasis and nephrolithiasis in HIV-positive patients in the era of combination antiretroviral therapy
|
KUAN-YIN LIN; Liao S.-H.; Liu W.-C.; Cheng A.; Lin S.-W.; Chang S.-Y.; Tsai M.-S.; Kuo C.-H.; Wu M.-R.; Wang H.-P.; Hung C.-C.; Chang S.-C. |
| 臺大學術典藏 |
2021-08-27T06:48:47Z |
Completion and adverse drug events of latent tuberculosis infection treatment in patients receiving dialysis: Predictors and impacts of different regimens in a prospective cohort study
|
Lin S.-Y.; Feng J.-Y.; Lee C.-Y.; Lin Y.-C.; Chou Y.-H.; KUAN-YIN LIN; Wei Y.-F.; Lin S.-W.; Chang C.-H.; Wang P.-H.; Shu C.-C.; Wang J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-25T01:53:16Z |
Cholelithiasis and nephrolithiasis in HIV-positive patients in the era of combination antiretroviral therapy
|
KUAN-YIN LIN; Liao S.-H.; Liu W.-C.; Cheng A.; Lin S.-W.; Chang S.-Y.; Tsai M.-S.; Kuo C.-H.; Wu M.-R.; Wang H.-P.; Hung C.-C.; Chang S.-C. |
| 臺大學術典藏 |
2021-08-25T01:53:03Z |
Completion and adverse drug events of latent tuberculosis infection treatment in patients receiving dialysis: Predictors and impacts of different regimens in a prospective cohort study
|
Lin S.-Y.; Feng J.-Y.; Lee C.-Y.; Lin Y.-C.; Chou Y.-H.; KUAN-YIN LIN; Wei Y.-F.; Lin S.-W.; Chang C.-H.; Wang P.-H.; Shu C.-C.; Wang J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-24T08:23:34Z |
Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients
|
YU-SHAN HUANG; Chan C.-K.; Tsai M.-S.; Lee K.-Y.; Lin S.-W.; Chang S.-Y.; Hung C.-C.; Chang S.-C. |
| 臺大學術典藏 |
2021-08-24T08:01:29Z |
Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients
|
Huang Y.-S.; CHIEH-KAI CHAN; Tsai M.-S.; Lee K.-Y.; Lin S.-W.; Chang S.-Y.; Hung C.-C.; Chang S.-C. |
| 臺大學術典藏 |
2021-08-24T01:49:34Z |
Completion and adverse drug events of latent tuberculosis infection treatment in patients receiving dialysis: Predictors and impacts of different regimens in a prospective cohort study
|
Lin S.-Y.; Feng J.-Y.; Lee C.-Y.; YI-CHIH LIN; Chou Y.-H.; Lin K.-Y.; Wei Y.-F.; Lin S.-W.; Chang C.-H.; Wang P.-H.; Shu C.-C.; Wang J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-23T23:47:19Z |
Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression
|
Huang W.-C.; Huang C.-K.; Huang S.-H.; Lin S.-W.; Ou S.-T.; YI-TING CHEN; Chen Y.-W.; Chang S.-Y.; Liu W.-C.; Sun H.-Y.; Hung C.-C. |
| 臺大學術典藏 |
2021-08-23T23:47:18Z |
Targeting fibroblast CD248 attenuates CCL17-expressing macrophages and tissue fibrosis
|
Pai C.-H.; Lin S.-R.; Liu C.-H.; Pan S.-Y.; Hsu H.; YI-TING CHEN; Yen C.-T.; Yu I.-S.; Wu H.-L.; Lin S.-L.; Lin S.-W. |
| 臺大學術典藏 |
2021-08-20T08:50:14Z |
Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia
|
Lai C.-C.; Lee K.-Y.; Lin S.-W.; Chen Y.-H.; HAN-YUEH KUO; Hung C.-C.; Hsueh P.-R. |
| 臺大學術典藏 |
2021-08-20T07:25:53Z |
Impact of Efavirenz Mid-dose Plasma Concentration on Long-Term Weight Change Among Virologically Suppressed People Living With HIV
|
Huang S.-H.; Huang W.-C.; Lin S.-W.; YU-CHUNG CHUANG; Sun H.-Y.; Chang S.-Y.; Kuo P.-H.; Wu P.-Y.; Liu W.-C.; Chiang C.; Hung C.-C.; Chang S.-C. |
| 臺大學術典藏 |
2021-08-20T07:10:54Z |
Impact of Efavirenz Mid-dose Plasma Concentration on Long-Term Weight Change Among Virologically Suppressed People Living With HIV
|
Huang S.-H.; Huang W.-C.; Lin S.-W.; Chuang Y.-C.; HSIN-YUN SUN; Chang S.-Y.; Kuo P.-H.; Wu P.-Y.; Liu W.-C.; Chiang C.; Hung C.-C.; Chang S.-C. |
| 臺大學術典藏 |
2021-08-20T04:24:47Z |
Impact of Efavirenz Mid-dose Plasma Concentration on Long-Term Weight Change Among Virologically Suppressed People Living With HIV
|
Huang S.-H.; Huang W.-C.; Lin S.-W.; Chuang Y.-C.; Sun H.-Y.; Chang S.-Y.; Kuo P.-H.; Wu P.-Y.; Liu W.-C.; Chiang C.; Hung C.-C.; SHAN-CHWEN CHANG |
